{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:55:25Z","timestamp":1790902525908,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":282,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Spine"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.bas.2024.103923","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T06:34:52Z","timestamp":1728542092000},"page":"103923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-4626","authenticated-orcid":false,"given":"Mark P.","family":"van Opijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.A.","family":"Nabuurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-5991","authenticated-orcid":false,"given":"Filip Y.F.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini T.R.","family":"Ramsoedh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-0793","authenticated-orcid":false,"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-0035","authenticated-orcid":false,"given":"Marjolein","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike L.D.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bas.2024.103923_bib1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jvs.2015.12.040","article-title":"Quality assessment of peripheral artery disease clinical guidelines","volume":"63","author":"Barriocanal","year":"2016","journal-title":"J. Vasc. Surg."},{"issue":"18","key":"10.1016\/j.bas.2024.103923_bib2","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"Agree II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"5","key":"10.1016\/j.bas.2024.103923_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/neuonc\/noad008","article-title":"EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection","volume":"25","author":"Capper","year":"2023","journal-title":"Neuro Oncol."},{"issue":"28","key":"10.1016\/j.bas.2024.103923_bib5","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bas.2024.103923_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174831","article-title":"Guideline appraisal with AGREE II: systematic review of the current evidence on how users handle the 2 overall assessments","volume":"12","author":"Hoffmann-E\u00dfer","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bas.2024.103923_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41430-021-01036-8","article-title":"Evidence-based nutrition guidelines for cancer survivors in Europe: a call for action","volume":"76","author":"Keaver","year":"2022","journal-title":"Eur. J. Clin. Nutr."},{"issue":"5","key":"10.1016\/j.bas.2024.103923_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bas.2024.103923_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2018.03.001","article-title":"Quality assessment of clinical practice guidelines on treatments for oral cancer","volume":"65","author":"Madera","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.bas.2024.103923_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.bas.2024.103923_bib11","doi-asserted-by":"crossref","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp","year":"2014","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.bas.2024.103923_bib12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bas.2024.103923_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12920-022-01343-4","article-title":"Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study","volume":"15","author":"van Opijnen","year":"2022","journal-title":"BMC Med. Genom."},{"issue":"4","key":"10.1016\/j.bas.2024.103923_bib14","first-page":"360","article-title":"Practice variation in re-resection for recurrent glioblastoma: a nationwide survey among Dutch neuro-oncology specialists","volume":"10","author":"van Opijnen","year":"2023","journal-title":"Neurooncol Pract"},{"issue":"3","key":"10.1016\/j.bas.2024.103923_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bas.2024.103923_bib16","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1200\/JCO.2009.26.9027","article-title":"Bevacizumab and recurrent malignant gliomas: a European perspective","volume":"28","author":"Wick","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Brain and Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772529424011792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772529424011792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:21:59Z","timestamp":1790900519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772529424011792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"alternative-id":["S2772529424011792"],"URL":"https:\/\/doi.org\/10.1016\/j.bas.2024.103923","relation":{},"ISSN":["2772-5294"],"issn-type":[{"value":"2772-5294","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation","name":"articletitle","label":"Article Title"},{"value":"Brain and Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bas.2024.103923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of EUROSPINE, the Spine Society of Europe, EANS, the European Association of Neurosurgical Societies.","name":"copyright","label":"Copyright"}],"article-number":"103923"}}